×

Biotech and Pharmaceuticals Medicine

  • LAKE BUENA VISTA, Florida, Dec 15- Just outside the operating theater, the organizers of a medical conference wore Minnie Mouse ears. They were part of a so-called cadaver lab and the setting was a Florida resort. In this case, doctors practiced nerve root blocks and other procedures on cadavers in one of the Grand Harbor ballrooms salons at Disneys Yacht& Beach Club...

  • LAKE BUENA VISTA, Florida, Dec 15- LAKE BUENA VISTA, Florida Just outside the operating theater, the organizers of a medical conference wore Minnie Mouse ears. They were part of a so-called cadaver lab and the setting was a Florida resort. In this case, doctors practiced nerve root blocks and other procedures on cadavers in one of the Grand Harbor ballrooms salons at...

  • Start-up programs video games that could be prescribed as medicine

    Akili, a Boston-based tech company, hopes to one day have doctors prescribe their video games to help treat cognitive and neurological conditions, CNBC’s Meg Tirrell reports.

  • Earlier this week, the FDA determined additional review time was necessary for Pfizer's application to market Xeljanz as a treatment for ulcerative colitis, a bowel disease. In 2015, the FDA rejected it as a treatment for a scaly skin condition called plaque psoriasis. On Wednesday, Pfizer said it secured an FDA nod for its second biosimilar version of Johnson&...

  • CHICAGO, Dec 13- A new study sheds light on how the mosquito-borne Zika virus causes a rare neurological condition, and the findings could have implications for companies working on Zika vaccines, U.S. researchers said on Wednesday. The Zika outbreak that swept through the Americas in 2015 and 2016 showed the virus could, in rare cases, cause Guillain-Barre, an...

  • Dec 13- Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz. Lilly said it was expecting a regulatory decision on its rheumatoid arthritis drug baricitinib, whose marketing application was initially rejected by the U.S. Food and Drug...

  • "The data support the early use of carfilzomib as an effective therapy at first relapse, regardless of prior treatment with Velcade or transplant," Keith Stewart, principal investigator on the study said, referring to Takeda Pharmaceutical Co's cancer treatment. FDA requesting to include the new overall survival data in the drug's label.

  • Retail prescriptions set to reach $4 billion this year.

    Having health insurance is supposed to save you money on prescriptions. But increasingly, consumers are finding that isn't the case, ProPublica reports.

  • Dec 11- Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer. The company said it had filed for marketing approval with the U.S. regulator based on the results of the trial, requesting to update the Kyprolis label to include the new...

  • Dec 11- Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday. The overall response rate was 41.6 percent, according to data unveiled at...

  • Spark Therapeutics CEO on future of genetic therapies

    Spark Therapeutics CEO Jeff Marrazzo speaks to CNBC's Meg Tirrell about the biotech company's hemophilia treatments and the potential for gene therapies.

  • Dec 11- The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating. According to the Centers for...

  • Dec 11- The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting insulin product, generally administered just before meals, to help patients with diabetes control blood sugar levels after eating.

  • LONDON, Dec 11- Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease. Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability of the drug...

  • LONDON, Dec 11- Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease. The success in the early-stage clinical trial has prompted Roche to exercise its option to license the product, called...

  • LONDON, Dec 11- Scientists have for the first time fixed a protein defect that causes Huntingdon's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease. Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability of the drug...

  • LONDON, Dec 11- GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters. In his first public comments since joining GSK in September, Luke Miels said the focus would be mainly on buying or licensing early-stage drugs.

  • The results indicate that, in the 81- patient study, those with no sign of cancer after three months remained relapse-free at six months and beyond, researchers reported at the American Society of Hematology meeting in Atlanta. Stephen Schuster, the trial's lead investigator, who has patients from an earlier pilot study alive more than three years after...

  • BLUEBIRD BIO, CELGENE CAR-T THERAPY LEADS TO COMPLETE REMISSION IN 56 PCT OF MULTIPLE MYELOMA PATIENTS- STUDY.

  • Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology. "This is an extremely valuable therapy for some patients who have no other options," said Dr Frederick...